Is lirentelimab the ‘magic bullet’ to fight pathological mast-cell activation in systemic mastocytosis?

Journal Article Corrected proof Is lirentelimab the ‘magic bullet’ to fight pathological mast-cell activation in systemic mastocytosis? Get access Stéphane Barete, Stéphane Barete Reference center for mastocytosis (CEREMAST), AP-HP, GH Pitié-Salpêtrière, 47–83 bd de l’Hôpital 75013 Paris and Sorbonne Université, Paris Correspondence: Stéphane Barete. Email: stephane.barete@aphp.fr https://orcid.org/0000-0003-1593-9750 Search for other works by this author on: Oxford Academic Google Scholar Michel Arock Michel Arock Reference center for mastocytosis (CEREMAST), AP-HP, GH Pitié-Salpêtrière, 47–83 bd de l’Hôpital 75013 Paris and Sorbonne Université, Paris Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljad227, https://doi.org/10.1093/bjd/ljad227 Published: 05 July 2023 Article history Received: 27 June 2023 Accepted: 03 July 2023 Published: 05 July 2023 Corrected and typeset: 10 August 2023